KPW
SRPT icon

Kore Private Wealth’s Sarepta Therapeutics SRPT Stock Holding History

Kore Private Wealth’s Portfolio SRPT Stock Details SRPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-375
Closed -$60K – 963
2020
Q2 		$60K Hold
375
– – 0.01% 425
2020
Q1 		$37K Sell
375
-51
-12% -$5.83K 0.01% 476
2019
Q4 		$55K Buy
+426
New +$43K 0.01% 466

Other funds holding SRPT

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Kore Private Wealth's SRPT Position: Q3 2020 in Review

Kore Private Wealth sold out of Sarepta Therapeutics (SRPT) in Q3 2020, closing a stake of 375 shares — an estimated $60K sold.

Kore Private Wealth first reported a position in SRPT in Q4 2019 and held it in 3 quarters. The position peaked at $60K in Q2 2020. 403 funds tracked by Wall St. Rank hold SRPT as of Q3 2020.

  • Kore Private Wealth reported no remaining Sarepta Therapeutics position as of Q3 2020 after selling out during the quarter.
  • Kore Private Wealth sold 375 Sarepta Therapeutics shares in Q3 2020, an estimated $60K.
  • Kore Private Wealth first reported a position in Sarepta Therapeutics in Q4 2019 and held it in 3 quarters.
  • Kore Private Wealth's Sarepta Therapeutics position peaked at $60K in Q2 2020.
  • 403 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q3 2020.

Based on Kore Private Wealth's 13F filing for Q3 2020, filed 13 Nov 2020.